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Introduction
Eosinophilic granulomatosis with polyangiitis (EGPA), is a rare but potentially life-threatening disease 
with few effective treatments (1–3). The initial phase, characterized by asthma and other allergic symp-
toms, is followed by tissue and blood hypereosinophilia, and later by systemic necrotizing vasculitis (1–3). 
Eosinophils, which typically represent approximately 1% of  peripheral blood leukocytes (4), reach 10% 
or greater in EGPA (3). Eosinophils accumulate in the extravascular space, sometimes in pathognomonic 
granulomas. Their aggregation and activation around small vessels result in ischemic or thrombotic tissue 
damage (“vasculitis”) (3). Accordingly, treatment with anti–IL-5 mAb yields clinical improvement in some 
patients (2). Hypereosinophilia alone — which also occurs in medication reactions, hematologic malignan-
cy, allergy, or parasite infection — is not sufficient to cause vasculitis (5–8). But it remains unclear what 
additional signals induce disease, or what tissue specific signals explain predilection for particular organs 
such as airways, peripheral nerves, skin, and heart (3).
Given the similarities with allergic asthma, the presumption has been that eosinophil activity is driven 
by Th type 2 (Th2) cells. However, this hypothesis remains unproven, in part because rodent models that 
recapitulate human disease are lacking (3). In addition, a role for type 2 innate lymphoid cells (ILC2s), 
tissue-resident innate counterparts to Th2 cells that are highly responsive to IL-25, TSLP, and IL-33 (9), has 
not been explored. ILC2s constitutively produce IL-5, which is important for controlling tissue accumula-
tion of  eosinophils (10) as well as other type 2 cytokines such as IL-4 and IL-13. In this study, we examine 
a role for tissue cytokines in activation of  ILC2s in patients with EGPA and establish a mouse model to 
study this complex and devastating disease.
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare but serious disease with poorly 
understood mechanisms. Here, we report that patients with EGPA have elevated levels of TSLP, 
IL-25, and soluble ST2, which are well-characterized cytokine “alarmins” that activate or modulate 
type 2 innate lymphoid cells (ILC2s). Patients with active EGPA have a concurrent reduction 
in circulating ILC2s, suggesting a role for ILC2s in the pathogenesis of this disease. To explore 
the mechanism of these findings in patients, we established a model of EGPA in which active 
vasculitis and pulmonary hemorrhage were induced by IL-33 administration in predisposed, 
hypereosinophilic mice. In this model, induction of pulmonary hemorrhage and vasculitis was 
dependent on ILC2s and signaling through IL4Rα. In the absence of IL4Rα or STAT6, IL-33–treated 
mice had less vascular leak and pulmonary edema, less endothelial activation, and reduced 
eotaxin production, cumulatively leading to a reduction of pathologic eosinophil migration into 
the lung parenchyma. These results offer a mouse model for use in future mechanistic studies of 
EGPA, and they suggest that IL-33, ILC2s, and IL4Rα signaling may be potential targets for further 
study and therapeutic targeting in patients with EGPA.
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Results
Patients with EGPA had elevated type 2 cytokines in serum and altered ILC2 numbers. We quantified increased 
serum levels of  IL-5 and IL-10 among patients with EGPA (Supplemental Figure 1, A and B; supplemen-
tal material available online with this article; https://doi.org/10.1172/jci.insight.143366DS1), particularly 
during active disease. We reasoned that alarmins known to potentiate IL-5 production might act upstream 
of  these effector cytokines in patients with EGPA. GWAS analysis identifies variants in the gene encoding 
TSLP in patients with EGPA (11), and both IL-25 (12) and IL-33 (13) have previously been reported to be 
elevated in patients with active EGPA. Indeed, we observed that patients with EGPA had elevated serum 
levels of  IL-25, TSLP, and soluble ST2 (sST2), the decoy receptor for IL-33 (Figure 1, A–C), whereas IL-33 
was not detected in serum from patients with EGPA or controls (data not shown).
Because these cytokines can activate ILC2s, a major source of  IL-5, we hypothesized that ILC2s 
might contribute to disease in patients with EGPA. Peripheral blood ILC2s were significantly decreased 
in patients with EGPA (Figure 1D and Supplemental Figure 1C). Because ILC2s are predominantly tissue 
resident (14), we hypothesize that elevated tissue cytokines may induce migration and retention of  circulat-
ing ILC2s into diseased tissues in EGPA, as previously described in allergic asthma (15).
IL-33 treatment in hypereosinophilic mice caused eosinophilic vasculitis. To test the role of  ILC2s and their 
activating cytokines in pathogenesis of  eosinophilic vasculitis, we employed a previously described mouse 
model wherein IL-5 is expressed as a transgene from the CD3δ promoter (herein designated as “IL5Tg”), 
resulting in approximately 100-fold normal levels of  circulating eosinophils (>60% of  total peripheral 
blood leukocytes, progressive with age) (5). These mice have diffuse organ infiltration with eosinophils, 
splenomegaly, and lymphocytosis but do not exhibit spontaneous eosinophilic vasculitis.
Treatment of  IL5Tg mice intranasally with IL-33 but not IL-25, TSLP, or saline over a 2-week peri-
od led to alveolar hemorrhage (Figure 2, A and B, and Supplemental Figure 3A). Saline-treated IL5Tg 
mice showed pulmonary eosinophilia with peribronchovascular eosinophilic clusters (Figure 2C), as pre-
viously described (5, 8). IL-33–treated WT mice showed lymphocytic infiltration and perivascular lym-
phoid aggregates, consistent with lymphocytic pneumonia (Figure 2C). In contrast, lungs of  IL-33–treated 
IL5Tg mice showed dense patches of  perivascular and peribronchial inflammatory infiltrates, individual 
and clustered multinucleated giant cells, nodular areas of  necrosis, intra-alveolar fibrin deposits, eosino-
philic vasculitis, and alveolar hemorrhage (Figure 2C and Supplemental Figure 3, B–G). Treatment of  
IL5Tg mice with IL-33, but not IL-25 or TSLP, also induced a synergistic increase in bronchoalveolar 
lavage (BAL) eosinophilia (Figure 2D and Supplemental Figure 2). IL-33 dramatically increased ILC2s 
in the BAL in both WT and IL5Tg mice (Figure 2E), as previously described (16). The number of  eosino-
phils and ILC2s in lung tissue and BAL were closely correlated, indicating the utility of  BAL in assessing 
the tissue inflammatory state (Supplemental Figure 3, H and I).
EGPA can manifest in numerous tissues, including skin. Although we observed collections of  eosin-
ophils in skin of  saline-treated IL5Tg mice, the cutaneous vessels appeared normal (Supplemental Fig-
ure 3J). However, when IL5Tg mice were treated with IL-33, we observed eosinophilic infiltration of  the 
perivascular space and vascular walls (Supplemental Figure 3J). Antineutrophil cytoplasm Abs (ANCAs), 
which are found in about a third of  patients with EGPA (17), were not increased in IL5Tg mice, with or 
without cytokine treatment (data not shown). Thus, IL-33 treatment of  IL5Tg mice recapitulated aspects 
of  eosinophilic vasculitis in patients with EGPA.
ILC2s were required for the development of  vasculitis in hypereosinophilic mice. To test the role of  ILC2s in 
vasculitis, we crossed IL5Tg mice to Il5Red5CreROSA-DTA ILC2-deficient R5/R5 deleter (ILC2del) mice, in 
which mature ILC2s — which constitutively produce IL-5 — are deleted via Cre-inducible expression of  
diphtheria toxin alpha from the endogenous IL-5 promoter (10). ILC2del x IL5Tg mice were protected from 
pulmonary hemorrhage after IL-33 (Figure 3A) and had dramatically blunted BAL eosinophilia (Figure 
3B) despite insignificant changes in peripheral eosinophilia (Supplemental Figure 4B). As expected, ILC2s 
were absent from the BAL in ILC2del mice (Figure 3C). ILC2del mice were rescued from histopathologic 
findings of  eosinophilic vasculitis (Figure 3D). Even during IL-33 administration, ILC2s were the predom-
inant population of  IL-5–expressing cells in the mouse lung (Supplemental Figure 4A), indicating that 
deletion of  Th2 cells was unlikely to explain the absence of  vasculitis.
IL4Rα signaling was required for the development of  vasculitis in hypereosinophilic mice. ILC2s produce numer-
ous effector molecules, including IL-5, IL-13, IL-9, and amphiregulin (9). We reasoned that in the context 
of  systemic IL-5 overexpression, the contribution of  ILC2-derived IL-5 was likely negligible. After IL-33 
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administration, ILC2s were the major IL-13–producing cell type in the lung (Figure 3E), suggesting that 
ILC2-derived IL-13 might have been implicated in the pathogenesis of  eosinophilic vasculitis in our model.
To investigate the role of  IL4Rα signaling in our model, we generated IL5Tg mice with cells 
unresponsive to IL-4 and IL-13 signaling by crossing to IL4Rα–/– (the receptor for IL-4 and IL-13) or 
STAT6–/– (required for downstream signaling). Like ILC2del mice, IL4Rα–/– x IL5Tg and STAT6-–/– x 
IL5Tg mice were protected from pulmonary hemorrhage after IL-33 administration (Figure 4A) and 
had dramatically reduced BAL eosinophilia compared with controls (Figure 4B). The number of  ILC2s 
in the BAL, however, was unaffected in STAT6–/– mice and minimally affected by the loss of  IL4Rα 
(Figure 4C). Thus, IL-4 and IL-13 signaling is dispensable for ILC2 expansion and appearance in the 
BAL and may rather be necessary for their pathologic effect. Consistent with the loss of  hemorrhage 
and eosinophils from BAL, IL5Tg mice on either IL4Rα–/– or STAT6–/– backgrounds were rescued from 
histopathologic evidence of  eosinophilic vasculitis (Figure 4, D–H). The degree of  rescue was more 
profound with STAT6–/– or IL4Rα–/– than with ILC2del (Figure 4, E–H), suggesting either incomplete 
deletion of  ILC2s or production of  IL-13 or IL-4 by other cells. Importantly, STAT6–/– x IL5Tg or 
IL4Rα–/– x IL5Tg mice had comparable blood eosinophilia, and ILC2 expansion after IL-33 treatment 
was equivalent (Supplemental Figure 5, A and B).
IL-33 caused IL4Rα-dependent acute lung injury and pulmonary vascular leak. We suspected that IL-33-in-
duced IL4Rα/STAT6-dependent signal(s) give eosinophils access to tissue-derived factors, resulting in 
degranulation and pathology. Indeed, IL-33 treatment caused severe pulmonary edema, as measured by 
excess/extravascular lung water (ELW), and increased vascular permeability, as measured by extravascular 
Figure 1. Patients with EGPA have elevated type 2-activating cytokines and altered ILC2 numbers in blood. (A) IL-25, (B) 
sST2, and (C) TSLP from HCs or patients with EGPA with iEGPA or aEGPA. n = 20–53 per group. (D) Peripheral blood ILC2s 
measured from HCs or patients with EGPA with iEGPA or aEGPA. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05 by 
Brown-Forsythe and Welch ANOVA with Dunnett’s post hoc testing. n = 6–18 patients per group. EGPA, eosinophilic gran-
ulomatosis with polyangiitis; ILC2s, type 2 innate lymphoid cells; sST2, soluble ST2; HCs, healthy controls; iEGPA, inactive 
disease; aEGPA, active disease. 
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plasma equivalents (EVPE; Figure 5, A and B). In contrast, TSLP did not increase ELW or EVPE, and 
IL-25 caused substantially less pulmonary edema than IL-33 (Supplemental Figure 6, A and B).
Pulmonary edema resulted in a loss of  static compliance (Figure 5, C and D) and reduced inspiratory 
capacity indicative of  a restrictive physiology (Figure 5E) that was unaffected by the IL5Tg. We did not 
observe airway hyperreactivity suggestive of  asthma (Supplemental Figure 6, C–F), suggesting this model 
more accurately reflects the active vasculitis phase of  EGPA than the asthmatic, prodromal phase.
We hypothesized that IL-33 treatment may act through ILC2s to stimulate IL-13 production, leading to 
acute lung injury, vascular permeability, and resulting pulmonary edema. Consistent with this hypothesis, 
we found that ILC2-deficient or IL-4 and IL-13 signaling–deficient mice had significantly reduced ELW and 
EVPE after IL-33 compared with WT mice (Figure 5, F and G). Comparatively, Rag1–/– mice were not pro-
tected from increased ELW and EVPE after IL-33, suggesting that the IL-4 and IL-13 signaling that induced 
vascular permeability and pulmonary edema was not dependent on T cells (Supplemental Figure 6, G and H).
Signaling through IL4Rα-mediated movement of  eosinophils from the vasculature to the extravascular space. 
Because IL5Tg mice on ILC2del, STAT6–/– or IL4Rα–/– backgrounds had severe hypereosinophilia but 
few pulmonary intraparenchymal eosinophils and no vasculitis, we suspected that IL4Rα signaling 
might promote eosinophil migration into tissue. Few lung eosinophils from saline-treated WT or IL5Tg 
mice remained unlabeled after intravenous injection of  anti-CD45 Ab, consistent with predominantly 
intravascular localization (Figure 6A). After IL-33 treatment, however, more than 90% of  the pulmo-
nary eosinophils were unlabeled, consistent with tissue entry (Figure 6A and Supplemental Figure 7A). 
Figure 2. IL-33 and hypereosinophilia synergize to cause eosinophilic vasculitis in mice. (A) Representative bronchoalveolar lavage and (B) representative 
whole lungs from IL-33–treated WT or IL5Tg mice. Images in A and B are representative of 3 or more mice/group, in a minimum of 3 independent exper-
iments. (C) H&E staining of lungs from representative IL-33–treated WT or IL5Tg mice, as shown in A and B (original magnification, ×20). Scale bars: 100 
μm. (D) Eosinophils or (E) ILC2s in BAL. Data are presented as ± SEM. ****P < 0.0001; ***P < 0.001 by 1-way ANOVA with Sidak post hoc testing. n = 3–4 
mice/group. BAL, bronchoalveolar lavage; ILC2s, type 2 innate lymphoid cells.
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By comparison, only approximately 50% as many eosinophils reached the extravascular space in IL-33–
treated IL4Rα–/– or IL4Rα–/– x IL5Tg mice (Figure 6A and Supplemental Figure 7B).
Signaling via IL4Rα is known to stimulate the production of  the chemokine eotaxin by multiple lung 
cell types in patients with asthma (18). Consistent with these clinical observations, we found that both 
IL4Rα–/– mice and IL4–/–/IL13–/– mice had significantly decreased levels of  eotaxin in serum in the unper-
turbed state (Figure 6B). Further, eotaxin levels in both BAL and serum were strongly induced after IL-33 
treatment in WT mice but not in IL4Rα–/– mice (Figure 6, C and D). Although ILC2del mice did not have 
decreased serum eotaxin at baseline, we reasoned that in the setting of  IL-33–induced ILC2 activation 
and IL-13 production, eotaxin levels may depend on ILC2s. Indeed, eotaxin was strongly induced in 
BAL and serum of  WT but not in ILC2del mice after IL-33 treatment (Figure 6, E and F). In addition to 
stimulating eotaxin production, IL-4 and IL-13 are also known to activate endothelial cells to upregulate 
surface VCAM-1 (19, 20), which can mediate eosinophil arrest and migration (21). Indeed, IL-33–treated 
IL4Rα–/– mice showed reduced vascular staining for VCAM- 1 (Supplemental Figure 7C) compared with 
controls. By comparison, PECAM-1 was minimally present and unchanged, and ICAM-1 was equally 
and ubiquitously expressed on epithelial cells, suggesting VCAM-1 upregulation as a mechanism through 
which IL-13 acts to potentiate eosinophil tissue ingress.
Discussion
Here we suggest a role for ILC2s and IL4Rα signaling in the pathogenesis of  EGPA and generate a mouse 
model for study of  this rare but disabling disease. We find that patients with EGPA had increased levels of  
IL-25, TSLP, and sST2 in serum and had a decrease in circulating ILC2s. We present a mouse model of  
eosinophilic vasculitis that recapitulates key aspects of  human EGPA, in which IL-33 induces ILC2- and 
IL4Rα/STAT6-dependent transformation of  established hypereosinophilia into severe tissue inflammation.
Our finding of  elevated IL-25, TSLP, and sST2 in patients with EGPA corroborates previous reports 
(12, 13). Though we could not reliably measure IL-33 in this study, we note that the interpretation of  serum 
Figure 3. ILC2s are required for development of vasculitis in hypereosinophilic mice. (A) BAL from ILC2-deficient ILC2del x IL5Tg mice (representative 
of 3 mice/group). (B) Eosinophils or (C) ILC2s in BAL of IL-33–treated ILC2del x IL5Tg. ****P < 0.0001, **P < 0.01, *P < 0.05 by 1-way ANOVA with Sidak 
post hoc testing. n = 3–11 mice/group. (D) H&E of lungs from representative IL-33–treated IL5Tg or ILC2del x IL5Tg mice treated with IL-33 shown in A–C 
(original magnification, ×40). Scale bars: 100 μm. (E) Number of IL-13Sm13+ cells in lungs of saline-treated or IL-33–treated YYRS Smart13–knock-in mice 
expressing a modified human CD4 marker from the mouse IL-13 gene locus. ILC2 defined as lin–, Thy1.2+, CD3–, Arg1YFP+, Red5+. Data are presented as 
± SEM. n = 3–4 mice/group. BAL, bronchoalveolar lavage; ILC2s, type 2 innate lymphoid cells.
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IL-33 levels is complicated even when technically feasible due to sequestration by serum sST2 (22) — a 
system most likely devised to constrain IL-33 activity to the tissue of  origin to prevent immunopatholo-
gy. Further technical advances will be needed to determine whether IL-33 is elevated in affected tissues 
of  patients with EGPA. Whether these alarmins are cause or consequence of  injury remains uncertain. 
Immunopathology per se (e.g., damage attributable to excessive eosinophil degranulation in tissue) could 
be the sole cause for release of  these cytokines. However, the propensity of  EGPA to develop late in life and 
its fluctuating activity suggest that environmental triggers may be important in disease pathogenesis (23). 
Thus, a reasonable hypothesis is that environmental insults provoke the initial release of  cytokines such as 
IL-33 at the mucosal barrier and initiate transformation to the vasculitic phase in a previously hypereosino-
philic host, which then propagates further alarmin release and immunopathology.
Our finding that ILC2s were decreased in blood of  patients with EGPA also replicates other studies 
(24). A conflicting report compared patients with EGPA with patients with asthma, who likely have 
Figure 4. Deficiency of IL4Rα signaling protects from vasculitis in hypereosinophilic mice. (A) BAL from IL-33–treated IL5Tg, STAT6–/– x IL5Tg, or 
IL4Rα–/– x IL5Tg. Representative of 4 or more mice/group. (B) Eosinophils in BAL of mice from A. Data are presented as ± SEM. ****P < 0.0001; **P < 
0.01; *P < 0.05; ns = by 1-way ANOVA with Sidak post hoc testing. n = 2–4 mice/group. (C) ILC2s in BAL of mice from A. ***P < 0.001; *P < 0.05; ns = 
by 1-way ANOVA with Sidak post hoc testing. n = 2–4 mice/group. (D) H&E staining of lungs from representative IL-33–treated IL5Tg, STAT6–/– x IL5Tg 
or IL4Rα–/– x IL5Tg mice treated with IL-33, as shown in A–C (original magnification, ×10). Scale bars: 100 μm. (E) Histopathological scoring for infil-
trates, (F) alveolitis, (G) giant cells, and (H) pulmonary capillaritis in ILC2del, STAT6–/–, or IL4Rα–/– with or without IL5Tg after saline or IL-33 treatment. 
****P < 0.0001, ***P < 0.001, **P < 0.01; *P < 0.05 by 1-way ANOVA with Dunnett’s post hoc testing. n = 4–9 mice/group. Data are presented as 
± SEM. BAL, bronchoalveolar lavage; ILC2s, type 2 innate lymphoid cells.
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abnormal numbers of  circulating ILC2s (13). Though a decrease in circulating ILC2s seems paradoxical, 
we point out that ILC2s are largely tissue-resident. Circulating cells are capable of  populating peripheral 
tissue pools — which are largely regenerated by local progenitors — when turnover or demand is high 
(25–27). Thus, circulating ILC2s may be depleted during active EGPA because they are recruited to 
stressed or damaged tissues.
Though we and others found elevations in multiple tissue cytokines in patients, only IL-33 induced pul-
monary inflammation consisting of  a mixed cellular infiltrate, giant cells, pulmonary capillaritis, and eosin-
ophilic necrosis in hypereosinophilic mice. Mouse lung ILC2s are relatively insensitive to IL-25 compared 
with IL-33 (28) due to low expression of  the receptor (29). Although tissue-specific receptor expression and 
cytokine sensitivity in human ILC2s are not fully established (14, 30, 31), such data would inform cytokine 
candidacy for induction of  EGPA in patients and reveal patient-specific correlations between individual 
tissue cytokine changes and specific organ involvement.
Figure 5. IL-33 induces IL4Rα-dependent vascular leak, resulting in pulmonary edema. (A) ELW of saline-treated or IL-33–treated WT or IL5Tg mice.  
n = 3–13 mice/group. (B) EVPE measured from saline-treated or IL-33–treated WT or IL5Tg mice. n = 3–13 mice/group. (C) Pressure volume curves, (D) lung 
static compliance, and (E) lung inspiratory capacity in indicated mice. n = 6–8 mice/group. (F) ELW or (G) EVPE in genotypes as indicated. n = 3–9 mice/
group. Significance determined by 1-way ANOVA with Sidak post hoc testing (A, B, F, and G), or Brown-Forsyth and Welch ANOVA with Dunnett’s multiple 
comparisons test (D and E). ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05. Data are presented as ± SEM. EVPE, extravascular plasma equivalents; 
ELW, excess/extravascular lung water.
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IL-33 has been reported to directly increase endothelial activation and vascular permeability (32, 33). 
However, vascular leak was significantly improved by removal of  ILC2s or IL4Rα/STAT6 signaling in 
our system. Similarly, eosinophil extravasation was significantly inhibited by the loss of  IL4Rα signaling, 
at least in part due to reduced induction of  VCAM-1 and eotaxin. By our estimate, approximately 50% of  
the vascular leak and eosinophil migration after IL-33 treatment is ILC2 dependent and IL4Rα dependent, 
whereas the other 50% may be attributable to direct effects of  IL-33 on the endothelial or epithelial cells, 
or other mechanisms. In light of  their role in regulating pulmonary edema after IL-33 treatment, we find it 
notable that IL-33-responsive ILC2s reside in the structures that are most critical for clearing edema fluid in 
the lungs: the adventitial cuffs of  bronchovascular bundles (34).
Because ILC2s produce IL-13 in the inflamed lung but minimal IL-4 (35), IL-13 is more likely drive the 
phenotype, even though both cytokines signal through IL4Rα. Within this paradigm, IL-33 may activate ILC2s 
Figure 6. IL4Rα signaling facilitates eosinophil egress into tissue through recruitment and vascular activation. (A) 
Extravascular (unlabeled) eosinophils (single, live, CD45+, CD11b+, CD125–, SiglecF+, SSChi cells) from saline-treated or 
IL-33–treated lungs. n = 3 mice/group. (B) Eotaxin measured from serum of untreated mice as indicated. n = 3–9 mice/
group. (C) Eotaxin measured from BAL or (D) serum of saline-treated or IL-33–treated WT or IL4Rα–/– mice. n = 3–6 
mice/group. (E) Eotaxin measured from BAL or (F) serum of saline-treated or IL-33–treated WT or ILC2del mice. n = 6–7 
mice/group. Significance determined by 1-way ANOVA with Sidak (A, C, and D) Dunnett’s (B) or Tukey (E and F) post 
hoc testing; ****P < 0.0001; ***P < 0.001; *P < 0.05. Data are presented as ± SEM. BAL, bronchoalveolar lavage; ILC2s, 
type 2 innate lymphoid cells.
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to produce IL-13, which in turn stimulates eotaxin production from parenchymal cells. However, ILC2s have 
also been reported to produce eotaxin (36), and therefore it is possible that ILC2s themselves may be the source 
of this chemoattractant. Interestingly, we observed that although ILC2del rescued mice from alveolar hemor-
rhage and BAL hypereosinophilia, histopathologic findings were further improved in mice entirely deficient in 
IL-4 and IL-13 signaling. This difference may be due to ILC2s that produce IL-13 but not IL-5 (therefore not 
deleted in ILC2del mice) or other cell types that produce IL-13 or IL-4. Although the lack of protection from 
IL-33-induced pulmonary edema in Rag1–/– mice argues against a central role for T cells in the acute vasculitic 
phase, Th2 cells may be critical for the development of the asthmatic and infiltrative phases, whereas ILC2s 
drive the vasculitic phase. Of note, although the ectopic expression of IL-5 in our mice precludes the ability to 
investigate ILC2s as a source of IL-5, this is a point for further investigation among patients with EGPA.
Rare cases of vasculitic syndromes consistent with EGPA are reported during treatment with dupilumab, as 
well as with placebo, in the context of reduced corticosteroid dose in patients with asthma (37, 38). We surmise 
that some cases of EGPA may have been misdiagnosed as simple eosinophilic asthma in these trials rather than 
IL4Rα blockade leading to vasculitis per se. Dupilumab is associated with increases in circulating eosinophils 
(39), which seems undesirable in a disease characterized by hypereosinophilia and is worthy of caution. Howev-
er, because hypereosinophilia is insufficient to cause pathology without extravascular migration and activation, 
our findings raise the question of whether dual blockade of eosinophils and IL-33 or IL4Rα could be useful for 
therapy in EGPA. Indeed, because dupilumab decreases eotaxin expression in patients (39), augmented periph-
eral eosinophilia could be a direct consequence of blocking extravascular migration and activation.
In sum, using patient samples and mouse modeling, we suggest a mechanism for the transition from 
hypereosinophilia to vasculitis in EGPA. In this model, environmental insults or tissue damage led to the 
release of  tissue cytokines such as IL-33. This may have stimulated ILC2s to produce IL-13, which increases 
pulmonary vascular permeability, eotaxin, and VCAM-1 expression, facilitating the migration of  eosino-
phils into the extravascular space. Once in the extravascular space and in contact with activating tissue fac-
tors, these eosinophils degranulated and caused tissue damage, likely promoting further release of  activating 
alarmins. Our data provide a useful mouse model for further study of  this rare and complex disease and 
suggest that therapeutic targeting of  IL-33, IL4Rα, and/or ILC2s may offer benefit in eosinophilic vasculitis.
Methods
Patients with EGPA and healthy controls. Serum and PBMCs from healthy controls were obtained at the 
Etablissement Français du Sang, Saint-Antoine Hospital, Paris, France. Patients with EGPA, described 
in Tables 1 and 2, fulfilled the American College of  Rheumatology criteria (40) and the 2012 Chapel Hill 
Consensus Conference definition (1). Patients were determined to be in the active phase of  EGPA if  they 
had a Birmingham vasculitis activity score (BVAS; version 3.0) of  3 or greater (41), or in remission if  they 
had a BVAS of  0. Patients with EGPA were identified at the Vasculitis Reference Center for Vasculitis, 
Cochin Hospital, Paris, France, and patients with available frozen sera were selected for cytokines measure-
ment. Samples from age- and sex-matched healthy controls were provided to the investigators in blinded 
fashion by the Etablissement Français du Sang without demographics included.
Measurement of  cytokines and ILC2s from patients. PBMCs were purified from whole blood using Ficoll-
Hypaque (GE Healthcare) and analyzed on a LSR Fortessa (BD Biosciences). Viability was assessed using 
LIVE/DEAD viability assay (Thermo Fisher Scientific). A gating strategy for ILC2s is shown in Supplemental 
Figure 1C. sST2, IL-25, TSLP, and IL-33 were quantitated using commercially available ELISAs from Tebu Bio, 
Peprotech, eBioscience, and R&D Systems, respectively. IL-5 and IL-10 were quantified by Luminex (Thermo 
Fisher Scientific) using the Th1/Th2/Th17 Magnetic 8-Plex Panel. Abs are listed in Supplemental Table 1.
Mice. IL5Tg (5), Arg1YFP (42), Il5Red5Cre (Red5) (10), ILC2-deleted (ILC2del) (10); STAT6–/– (43), Smart13 
(35), IL4Rα–/– (44), and IL4–/–/IL13–/– (45) mice have been described. Mice were derived or backcrossed 
on a C57BL/6J background for more than 10 generations, and housed under specific pathogen–free condi-
tions with 12-hr light/day cycles and ad libitum access to food and water. Experiments were performed on 
age- and sex-matched male and female mice between 8 weeks and 16 weeks of  age, except for the eotaxin 
experiments, in which mice were 6 months of  age. IL-33 (BioLegend or R&D), TSLP (eBioscience), or 
IL-25 (R&D) were administered intranasally at 0.5 μg per dose, 3 times a week for 2 weeks, and mice were 
analyzed 1 day after the final dose. For intravascular labeling experiments, mice were injected intravenously 
with 3 μg of  anti-mouse CD45 Ab (clone 30-F11) 3 minutes prior to sacrifice. Eotaxin was measured from 
serum using the Mouse CCL11/Eotaxin Quantikine ELISA Kit (R&D).
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Mouse cell isolation and flow cytometry. PBMCs were isolated using Histopaque-1083 (Sigma). BAL 
was obtained by instilling 1.5 mL of  saline via tracheal cannulation, followed by saline perfusion. 
Lung single cell suspensions were obtained by tissue digestion with 50 μg/mL Liberase (Roche) and 
25 μg/mL DNAse I (Roche). Flow cytometry was performed on an LSR Fortessa and analyzed using 
FlowJo (Tree Star). Dead cells were excluded by LIVE/DEAD or DAPI. A representative gating strat-
egy for eosinophils and ILC2s is shown in Supplemental Figure 2. For IL-13 assessment by Smart13 as 
in Figure 3, lung ILC2s were gated as lineage-negative, Thy1.2+, CD3–, Arg1YFP+, Red5+. Abs are listed 
in Supplemental Table 1.
Microscopy. Four percent paraformaldehyde-fixed tissues were embedded in paraffin for H&E staining 
or OCT (Sakura) for immunofluorescence and imaged on a Leica light microscope (H&E) or Nikon A1R 
confocal microscope. Histologic appearance was evaluated in a blinded manner at a uniform anatomic 
position, and a severity score of  0 (none) to 3 (severe) was assigned for alveolitis, inflammatory infiltrates, 
and giant cells. Capillaritis was defined as presence (score, 1) or absence (score, 0) of  hemorrhage associat-
ed with perivascular infiltration of  macrophages, neutrophils, lymphocytes, and/or eosinophils. If  perivas-
cular infiltration was present without overt hemorrhage, images were scored as 0.5.
Table 1. Characteristics of patients with EGPA examined for serum cytokines





 Age, median [IQR] 49 [44–56] 52 [45–61]
 Women, n (%) 7 (35) 15 (43)
Disease activity
 BVAS, median [IQR] 13 [9–16] 0
Ongoing treatments
 None, n (%) 7 (35) 0 (0)
 Low-dose prednisone, n (%) 13 (65) 35 (100)
 Immunosuppressive agents, n (%) 6 (30) 26 (74)
Laboratory features
 MPO-ANCA, n (%) 8 (40) 14 (40)
Blood eosinophils, median [IQR]/mm3 2239 [1146–4460] 180 [51–770]
EGPA, eosinophilic granulomatosis with polyangiitis; ANCA, antineutrophil cytoplasm Abs; BVAS, Birmingham 
vasculitis activity.
 
Table 2. Characteristics of patients with EGPA examined for peripheral blood ILC2s





 Age, median [IQR] 54 [38–67] 56 [42–62]
 Women, n (%) 4 (57) 4 (67)
Disease activity
 BVAS, median [IQR] 15 [11–18] 0
Ongoing treatments
 None, n (%) 4 (57) 1 (17)
 Low-dose prednisone, n (%) 3 (43) 5 (83)
 Immunosuppressive agents, n (%) 1 (14) 2 (33)
Laboratory features
 MPO-ANCA, n (%) 2 (28) 1 (17)
 Blood eosinophils, median [IQR]/mm3 1645 [980–3333] 140 [50–930]
EGPA, eosinophilic granulomatosis with polyangiitis; ILC2s, type 2 innate lymphoid cells; ANCA, antineutrophil 
cytoplasm Abs; BVAS, Birmingham vasculitis activity.
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Lung physiology. Mice were anesthetized with ketamine and xylazine and intubated with an 18-gauge 
cannula for analysis on the FlexiVent FX NPFE and Aeroneb system (SciReq). Pancuronium was used to 
paralyze mice before studies of  lung mechanics and methacholine challenges at the indicated doses. ELW 
and EVPE were measured as previously described (46).
Statistics. Analyses were performed with GraphPad Prism 8 using 2-tailed nonparametric Mann-Whitney U 
test or 1-way ANOVA with post hoc testing as appropriate. Data shown in the figures represent mean ± SEM.
Study approval. For human studies, all subjects provided written informed consent according to the Dec-
laration of  Helsinki (CPP authorization number 2011-12767). Protocols were approved by the INSERM 
IRB (NEUTROVASC DR-2012-002) and the Hospital Cochin Ethics Committee. All procedures on mice 
were approved by the UCSF Animal Care and Use Committee.
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